Search results
Results From The WOW.Com Content Network
A lower dose should be used in people with liver disease. [2] While it does not appear to be harmful during pregnancy, it has not been studied for this use. [3] It is unclear if it is safe for use during breastfeeding. [2] It is in the antihelmintic family of medications. [4] It works by paralyzing worms. [4] Pyrantel was initially described in ...
A schistosomicide is a drug used to combat schistosomiasis. [1] List. Examples listed in MeSH include: [2] amoscanate; ... Schistosomiasis vaccine; References
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210. [1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V ...
Fontana, along with 35 others were given an immunotherapy drug alongside the vaccine. Liver cancer is one of the leading causes of cancer deaths worldwide, accounting for over 700,000 deaths each ...
Individualized cancer immunotherapy, also referred to as individualized immuno-oncology, is a novel concept for therapeutic cancer vaccines that are truly personalized to a single individual. The human immune system is generally able to recognize and fight cancer cells .
Personalized mRNA cancer vaccine therapy is a therapy that uses a personalized cancer vaccine based on mRNA vaccine technology to target existing tumors in patients. As of 2024, number of mRNA cancer vaccines are in clinical trials, of which many are personalized therapies based on engineering mRNA-mediated immune response that targets the patient's particular strain of cancer cells.